Jammu And Kashmir Headlines

DelveInsight’s ‘Chronic Hepatitis B Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of the Chronic Hepatitis B, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

Key Takeaways from the Chronic Hepatitis B Market Report

• The increase in Chronic Hepatitis B Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Chronic Hepatitis B Market is anticipated to witness growth at a considerable CAGR.
• The total prevalent cases of Chronic Hepatitis B in the 7MM comprised approximately 56,333,000 cases in 2022 and are projected to decrease during the forecast period
• The total prevalent cases of Chronic Hepatitis B in the United States were around 22,56,700 cases in 2022.
• The leading Chronic Hepatitis B Companies working in the market include Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology and other.
• Promising Chronic Hepatitis B Pipeline Therapies in the various stages of development include RG6346, Pradefovir, VIR-3434, SBT8230, and Others.
• April 2024:- Ascletis Pharmaceuticals Co., Ltd.- Phase IIa Single Dose and Phase IIb Mutiple Dose Clinical Studies to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Subcutaneously Injected PD-L1 Antibody ASC22 in Patients With Chronic Hepatitis B.
• April 2024:- Gilead Sciences- A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB).
• April 2024:- Hoffmann-La Roche- A Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection.

 

Discover which therapies are expected to grab the Chronic Hepatitis B Market Share @ Chronic Hepatitis B Market Outlook

 

Chronic Hepatitis B Overview

Hepatitis B is a potentially life-threatening and one of the most common liver infections caused by the hepatitis B virus (HBV), which attacks and injures the liver. Hepatitis B is a “silent epidemic” because most people do not exhibit symptoms when newly or chronically infected. As a result, they have the potential to unintentionally infect others and prolong the slow spread of hepatitis B. If an individual suffers from a Hepatitis B virus infection that lasts more than 6 months, the infection becomes chronic. Chronic Hepatitis B increases the risk of developing liver failure, liver cancer, or cirrhosis. The risk of developing a Chronic hepatitis B infection is also directly related to the age at which one first becomes exposed to the hepatitis B virus. Males are more prone to develop Chronic hepatitis B.

 

Chronic Hepatitis B Epidemiology Insights

As the market is derived using the patient-based model, the Chronic Hepatitis B epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Chronic Hepatitis B, Total Diagnosed Prevalent Cases of Chronic Hepatitis B, Gender-specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Age-specific Diagnosed Prevalent Cases of Chronic Hepatitis B, Type-specific Diagnosed Prevalent Cases of Chronic Hepatitis B, and Total Treated Cases of Chronic Hepatitis B in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Download the report to understand which factors are driving Chronic Hepatitis B Epidemiology trends @ Chronic Hepatitis B Epidemiological Insights

 

Chronic Hepatitis B Drugs Market

The Chronic Hepatitis B Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Chronic Hepatitis B signaling in Chronic Hepatitis B are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Chronic Hepatitis B Treatment Market Landscape

The Chronic Hepatitis B treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Chronic Hepatitis B has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Chronic Hepatitis B treatment guidelines, visit @ Chronic Hepatitis B Treatment Market Landscape

 

Chronic Hepatitis B Market Outlook

The report’s outlook on the Chronic Hepatitis B market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Chronic Hepatitis B therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Chronic Hepatitis B drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Chronic Hepatitis B market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Chronic Hepatitis B Drugs Uptake

The drug chapter of the Chronic Hepatitis B report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Chronic Hepatitis B.

 

Major Chronic Hepatitis B Companies

Several Chronic Hepatitis B Companies working in the market include Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, and other.

 

Learn more about the FDA-approved drugs for Chronic Hepatitis B @ Drugs for Chronic Hepatitis B Treatment

 

Scope of the Chronic Hepatitis B Market Research Report

• Coverage- 7MM
• Chronic Hepatitis B Companies- Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, and other.
• Chronic Hepatitis B Pipeline Therapies- RG6346, Pradefovir, VIR-3434, SBT8230, and Others.
• Chronic Hepatitis B Market Dynamics: Chronic Hepatitis B Market Drivers and Barriers
• Chronic Hepatitis B Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Chronic Hepatitis B Drugs in development @ Chronic Hepatitis B Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Chronic Hepatitis B Market Overview at a Glance

4. Executive Summary of Chronic Hepatitis B

5. Chronic Hepatitis B Epidemiology and Market Methodology

6. Disease Background and Overview

7. Diagnosis of Hepatitis B Infection

8. Current Chronic Hepatitis B Treatment Practices

9. Chronic Hepatitis B Epidemiology and Patient Population

10. Chronic Hepatitis B Patient Journey

11. Key Endpoints in Chronic Hepatitis B Clinical Trials

12. Marketed Chronic Hepatitis B Therapies

13. Emerging Chronic Hepatitis B Therapies

14. Discontinued Chronic Hepatitis B Drugs

15. Chronic Hepatitis B: The 7MM Analysis

16. Chronic Hepatitis B Market Access and Reimbursement

17. Chronic Hepatitis B KOL Views

18. SWOT Analysis

19. Chronic Hepatitis B Unmet Needs

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/